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A recent study published inMolecular Cell describes a mechanism whereby oncogenic BRAF inhibits AMPK
in melanoma cells. This may explain why cancer cells expressing oncogenic BRAF grow under conditions of
metabolic stress and may provide new therapeutic opportunities to treat this life-threatening disease.
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PreviewsDuring cancer progression, tumor cells
acquire the so-called ‘‘hallmarks of
cancer,’’ including self-sufficiency in
growth signals and insensitivity to anti-
growth signals (Hanahan and Weinberg,
2000). Most human melanomas achieve
self-sufficiency in growth through acquisi-
tion of activating mutations in the protein
kinase BRAF (Wellbrock et al., 2004),
whichdeliversproliferationsignals through
the MEK/ERK pathway. However, a key
question that remains is how melanoma
cells adapt their glucose metabolism to
sustain growth in the stressful conditions
of the tumor microenvironment. A recent
study in Molecular Cell by Zheng et al.
(2009) describes an intriguing linkbetween
BRAF and AMP-activated protein kinase
(AMPK), thekeysensorofmetabolic stress
in eukaryotic cells. This study may explain
how oncogenic BRAF (V600EBRAF) over-
whelms the metabolic stress signals that
normally inhibit cell growth.
AMPK is activated in conditions of
‘‘low energy,’’ when the AMP:ATP ratio
increases. To conserve energy, AMPK
promotes catabolism (e.g., increased
glucose uptake and glycolysis) and blocks
anabolism (e.g., protein and lipid
synthesis). It also inhibits cell growth by
activating TSC2, an exchange factor/acti-
vator for thesmallGproteinRheb,which in
turn inhibits the protein kinasemammalian
target of rapamycin (mTOR), thereby
reducing protein translation. AMPK is
phosphorylated andactivated by aprotein
kinase called LKB1 (Hong et al., 2003),
a tumor suppressor that is mutated in
Peutz-Jeghers syndrome, a rare genetic
condition characterized by the presence
of benign harmatomas and an increased
lifetime risk of cancer (Hemminki et al.,
1998). It is thought that LKB1 is constitu-
tively active and that its ability to activate
AMPK is mediated by AMP binding toAMPK,whichprevents its dephosphoryla-
tion and allows the active enzyme to accu-
mulate.
Zheng and colleagues start by showing
that the cell-permeable AMPK activator
AICAR (5-aminoimidazole-4-carboxamide
ribonucleoside) does not activate AMPK
in V600EBRAF melanoma cells but does
activate AMPK in wild-type BRAF cells.
This suggests that V600EBRAF suppresses
AMPK activity in melanoma cells. Accord-
ingly, BRAF depletion by RNA interference
or MEK inhibition with small molecules
promotes AMPK activation in V600EBRAF
cells. Critically, AMPK activation still
requires LKB1, and the authors show that
ERK and RSK, two kinases constitutively
activated downstream of V600EBRAF,
phosphorylate LKB1 on S325 and S428,
respectively. Mutation of these residues
allowsAICARtoactivateAMPK in thepres-
ence of V600EBRAF, and strikingly, this
LKB1 double mutant blocks V600EBRAF-
driven proliferation and soft agar colony
formation.
Notably, even though ERK is activated
in the majority of melanoma cells, it only
phosphorylates LKB1 when V600EBRAF is
present, because V600EBRAF stimulates
formation of a ternary complex between
itself, LKB1, and ERK, whereas wild-type
BRAF cannot form this complex. ERK
signaling occurs within highly ordered
complexes coordinated by specialized
scaffold proteins (Kolch, 2005), and these
data suggest that V600EBRAF alters the
architecture of this pathway to allow ERK
to phosphorylate LKB1.
Although AMPK blocks cell growth, it
also promotes some events that could
be advantageous to tumor cells. Under
nutrient (particularly glucose) deprivation
or in hypoxia, AMPK stimulates glucose
uptake and increases expression of key
glycolytic enzymes (Ashrafian, 2006).Cancer CellThus, while inhibition of AMPK is neces-
sary to permit cell growth, when tumors
get large and nutrients and oxygen
become scarce, AMPK reactivation may
actually promote anabolic pathways and
cell growth. In their study, Zheng et al. do
not model the sustained elevation of
AMP that occurs in hypoxic or glucose-
deprived tumors, but they do show an
inverse correlation between AMPK and
ERK phosphorylation in human tumor
samples.While these datawere not corre-
lated to BRAF mutation status, they do
suggest that the BRAF-drivenmechanism
is physiologically relevant. Nevertheless, it
will be intriguing to determine whether
AMPK is still inhibited within the hypoxic
regions of V600EBRAF melanomas.
Taken together, the data above suggest
that V600EBRAF regulates metabolic
signaling directly, describing a V600EBRAF-
AMPK ‘‘axis’’ that allows proliferation
under metabolic stress (Figure 1A). They
suggest that this axis undermines normal
growth control to promote tumorigenesis
and imply that metabolic signals are thera-
peutic targets in melanoma. They also
describe a mechanism of LKB1 regulation
byphosphorylation, although the functions
of S325 and S428 in LKB1 regulation and
cell growth are controversial because
previous studies have failed to show clear
roles for these sites in LKB1 regulation
and effects (Sapkota et al., 2002; Fogarty
and Hardie, 2009; Denison et al., 2009).
Perhaps they have context-specific roles
that are only revealed, for example, in the
presence of V600EBRAF. It should also be
noted that the axis may be absent in
some V600EBRAF cells. V600EBRAF cannot
inhibit AMPK when LKB1 is reintroduced
into LKB1-deficient G361 melanoma cells
(Fogarty and Hardie, 2009), suggesting
that these cells can still grow when AMPK
is active or can inhibit AMPK through15, March 3, 2009 ª2009 Elsevier Inc. 163
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Previewsalternative mechanisms.
Finally, the RAF-AMPK axis
may be absent in RAS mutant
melanoma cells because RAS
signals exclusively through
CRAF (Dumaz et al., 2006),
which, like wild-type BRAF,
may be unable to support the
axis.
One aspect of the Zheng
et al. study yet to be explored
is the consequence of
impaired AMPK activation in
BRAF mutant melanoma
cells. The effects of AICAR on
cell growth are not described
by Zheng et al., and although
nonphosphorylatable LKB1
is shown to block cell growth,
the authors do not show
whether this is mediated by
AMPK or one of the twelve
other protein kinases that
LKB1 activates. Expression of an active
version of AMPK could answer this ques-
tion. Similarly, intriguingquestions relating
to the broader signaling network should
be answered. For example, AMPK is
thought to mediate growth suppression
through inhibition of mTOR, and the
authors argue that inhibition of AMPK is
necessary to allow mTOR activation.
However, V600EBRAF also activates RSK,
which is a direct activator of mTOR (Fig-
ure 1A), so why is LKB/AMPK inhibition
necessary when RSK is activated?
Presumably AMPK dominates RSK in
mTOR regulation, so RSK performs the
dual role of inhibiting the mTOR inhibitor
while simultaneously activating mTOR.
Clear answers to these questions will be
important to assist therapeutic strategy
design based on these studies.
Andwhat of the potential for therapeutic
intervention? The authors propose that
BRAF/MEK inhibitors together with
AMPK activators should offer an effective
therapeutic approach. This is interesting
and timely because the antidiabetic drug
metformin, which activates AMPK indi-
rectly, has been found to reduce lifetime
risk of cancer (Evans et al., 2005), and
potent and selectiveBRAF andMEKdrugs
are in clinical development. However, no
data are provided to support this notion,
and it is unclear whether such a combina-
tion would be better than monotherapies
that target BRAF/MEK. As Zheng et al.
show, MEK inhibitors activate AMPK, so
why would AMPK activators provide any
additional benefit (Figure 1B)? This ques-
tion goes to the heart of combination
therapy design. Will better responses be
achieved by inhibiting several pathways
simultaneously, or will ‘‘belt and braces’’
approaches that target single, critical
pathways at several nodes provide the
best response? Happily, in this case, we
have the tools and wherewithal to perform
thepreclinical studiesnecessary toanswer
the question.
Finally, what of other cancers harboring
mutations in BRAF, such as colorectal
(15% of cases), thyroid (30% of cases),
and ovarian (30% of cases) cancers?
Does V600EBRAF also rewire ERK to
phosphorylate LKB1 in those cancers,
and if so, can they also be
treated using therapies de-
signed for melanoma? Like
all good studies, the work
presented by Zheng et al. rai-
ses as many questions as it
answers, but importantly, it
points to strategies that may
provide therapeutic benefit
by combining drugs that
target growth and metabolic
signaling pathways. The
potential of these approaches
should now be tested.
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Figure 1. The V600EBRAF-AMPK Axis in Melanoma Cells
(A) V600EBRAF rewires the signaling pathway to allow ERK and RSK to phos-
phorylate and inhibit LKB1, thereby preventing AMPK activation. Together
with a positive signal from RSK, this stimulates mTOR activation, leading to
cell growth and proliferation.
(B) Inhibition of BRAF/MEK signaling causes a collapse in the downstream
network, allowing LKB1 to activate AMPK, which then inhibits mTOR. The
loss of these signaling pathways leads to inhibition of cell growth/proliferation.
Since these enzymes are part of the same pathway, it is unclear whether AMPK
activators will enhance the consequences of MEK/BRAF inhibition.164 Cancer Cell 15, March 3, 2009 ª2009 Elsevier Inc.
